Hyogo College of Medicine

Chugai Seiyaku Kabushiki Kaisha

Mitsubishi Tanabe Pharma Corporation

Mie University

Tomohiro Yoshimoto

Kenji Nakanishi

Hitoshi Mizutani

Joseph M Palumbo

Naoki Uyama

Koubun Yasuda

Jiro Fujimoto

Yasutomo Imai

Kiyofumi Yamanishi

Violetta I Stone

Toru Kato

Postoperative adhesion formation at an invasion site and migration of neutrophils to the site of surgical invasion are suppressed by administering an anti-IL-6 receptor antibody and/or a neutrophil-neutralizing antibody.

Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

IL-33 antagonist-containing therapeutic agent for endometriosis

The present invention provides a transgenic non-human mammal retaining, in a specifically expressible state, a DNA encoding IL-33 in the skin, and having one or more features selected from the group consisting of

Atopic dermatitis model animal and use thereof

The present invention provides a complex of an antigen and IgE binding to the antigen, a composition including an antigen and IgE binding to the antigen, and a method of using the complex or the composition to screen candidate therapeutics for TH-2 type diseases, for example in animal models.

Compositions, methods and animal models for screening therapeutics for TH2-type disease

Growing community of inventors

Nishinomiya, Japan

Tomohiro Yoshimoto